Navigation Links
H1N1 Influenza "Swine Flu" Peptide Vaccine Now Available For Testing Worldwide
Date:5/1/2009

Replikins, Ltd. has announced that it has produced a synthetic H1N1 swine flu vaccine, Replikins PanFlu™, which is ready for testing worldwide. The company has developed the vaccine based on the same Replikins peptide technology which provided the surprise advance warning one year ago that the current H1N1 outbreak/pandemic was on its way.

London, UK (PRWEB) May 1, 2009 -- Replikins, Ltd. has announced that it has produced a synthetic H1N1 swine flu vaccine, Replikins PanFlu™, which is ready for testing worldwide.

The company has developed the vaccine based on the same Replikins peptide technology which provided the surprise advance warning one year ago that the current H1N1 outbreak/pandemic was on its way.

In April 2008, Replikins, Ltd announced the likelihood of H1N1 outbreaks based on the company's patented Replikin Count™ genomics technology, which examines specific regions in virus genes that have been linked with past epidemics. The company's chairman, Dr. Samuel Bogoch, found that the regions have been conserved for decades. In H1N1 last year the company detected the highest concentrations of these specific regions ever seen, except for those from the 1918 flu pandemic which killed tens of millions of people. To date, no other method has been able to predict whether and what strain of a given organism will threaten a human or animal population.

The company is producing the new product after achieving test results against two previous viral outbreaks: the lethal Taura virus with shrimp populations and the avian flu (H5N1) with chicken populations. The company's closely related Replikins vaccine against avian flu, produced in a 7 day period, was recently tested at the University of Georgia and shown to block H5N1 virus entry, replication, and excretion in chickens (paper submitted for publication).

Institutions requesting Replikins' H1N1 vaccine for testing should contact: jmckenney @ replikins.com

http://www.replikins.com

# # #

Read the full story at http://www.prweb.com/releases/2009/05/prweb2384744.htm.


'/>"/>
Source: PRWeb
Copyright©2009 Vocus, Inc.
All rights reserved

Related biology technology :

1. Germgards Ultra-Fast Hand Hygiene Solution Protects Against Deadly MRSA, C difficile, and Influenza Virus
2. CEL-SCIs L.E.A.P.S. Technology Shows Potential to Treat Swine Influenza in Preclinical Studies
3. Hoviones TwinCaps(R) Inhaler in Phase III Clinical Trials for Influenza
4. NexBio Completes Clinical Advisory Board for the Advanced Development of DAS181 (Fludase(R)*), a First-In-Class Medicine for Influenza
5. NOVAVAX Announces Publication of a Preclinical Study Demonstrating that a Virus-like Particle Vaccine Provided Protection Against Highly Pathogenic H1N1 and H5N1 Influenza Strains
6. Confirmation of Bogoch Replikins Influenza Patents by Harvard-CDC and Scripps-Crucell Data
7. Schering-Plough Announces Collaboration With World Health Organization to Provide Access to Pandemic Influenza Vaccine Technology to Developing Countries
8. Fraunhofer USA Center for Molecular Biotechnology Receives Gates Foundation Grant for Avian Influenza Vaccine Development
9. Seasonal Influenza Activity Increasing Across Europe - H3N2 Dominant Strain
10. Rising H9N2 Influenza Replikin Count Has Doubled That of H5N1
11. DaVita Launches Flu Fighter Program in Support of National Influenza Week
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/2/2016)... ... December 02, 2016 , ... ... biotechnology companies dedicated to collaboratively developing improved chemistry, manufacturing and control technologies ... portable online UHPLC, with robust, probe-based sampling. , Online liquid chromatography ...
(Date:12/2/2016)... 1, 2016   SurePure, Inc. (OTCQB: SURP) ... the Company has concluded an agreement with Tamarack Biotics ... 90-day period to acquire units of the Company,s patented ... 3.7 million.  Concurrently with the option, ... which Tamarack will seek regulatory approvals in ...
(Date:12/2/2016)... world leader in rapid infectious disease tests, introduced the Company,s newest product, the INSTI ... (Photo: http://photos.prnewswire.com/prnh/20161201/444905 ) Continue Reading ... ... , bioLytical was invited by the Clinton ... HIV Self Test to 350 pharmacy representatives in Nairobi and ...
(Date:11/30/2016)... , Nov. 30, 2016  GenomOncology today announced the appointment ... of Medical Affairs.  Dr. Coleman will oversee ... company,s proprietary knowledge-enabled platform. The GenomOncology software suite empowers molecular ... sequencing data and clinical decision support, from quality control through ... , , ...
Breaking Biology Technology:
(Date:11/17/2016)... LONDON , Nov. 17, 2016 Global Market ... and Public Biobanks (Disease-Based Banks, Population-Based Banks and Academics) market ... Geographical analysis for Private Biobanks shows the highest Compounded Annual ... Asia-Pacific region during the analysis period 2014-2020. ... a CAGR of 9.95% followed by Europe ...
(Date:11/14/2016)... Nov. 14, 2016  xG Technology, Inc. ("xG" or ... critical wireless communications for use in challenging operating environments, ... 30, 2016. Management will hold a conference call to ... p.m. Eastern Time (details below). Key Recent ... $16 million binding agreement to acquire Vislink Communication Systems. ...
(Date:6/22/2016)... , June 22, 2016 On Monday, ... call to industry to share solutions for the Biometric ... U.S. Customs and Border Protection (CBP), explains that CBP ... are departing the United States , ... and to defeat imposters. Logo - ...
Breaking Biology News(10 mins):